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Upregulation of Lectin-like Oxidized LDL Receptor by Advanced Glycation 
End Products in Endothelial Cells 
 
Sammy Shiu, Ying Wong, Kathryn Tan. 
University of Hong Kong, Hong Kong 
  
Objective: Lectin-like oxidized LDL receptor-1 (LOX-1) is a class E oxidized LDL specific 
scavenger receptor and LOX-1 expression is inducible. LOX-1 has been implicated in 
atherogenesis and LOX-1 expression is increased in diabetes. It has been suggested that 
advanced glycation end products (AGE) may contribute to the induction of LOX-1 in diabetes 
and we have investigated the signaling pathway(s) involved. 
 
Methods: Human aortic endothelial cells were treated with AGE-BSA or BSA in the presence or 
absence of either antibody of receptor for advanced glycation end products (anti-RAGE), 
mammalian target of rapamycin (mTOR) inhibitor rapamycin, NF-kB inhibitor (BAY11-7085) 
or phosphoinositide 3-kinases (PI3K) inhibitor (LY294002). Western blot analyses on LOX-1, 
phosphorylation status of phosphoinositide-dependent kinase 1 (p-PDK1) and p-mTOR protein 
were performed. 
 
Results: AGE-BSA induced LOX-1 expression in a dose-dependent manner and pretreatment 
with anti-RAGE antibody resulted in a significant reduction in LOX-1 expression. The effect of 
AGE-BSA on LOX-1 expression was not blocked by BAY11-7085 but by rapamycin. Adding 
rapamycin reduced protein expressions of p-mTOR by 41% (p<0.05), and LOX-1 by 61.5% 
(p<0.01), suggesting involvement of mTOR signaling. To investigate whether AGE/RAGE 
interaction triggered mTOR signaling via activation of PI3K, cells were pretreated with 
LY294002. This resulted in a reduction of p-PDK1 (downstream effector molecule of PI3K) by 
26.7% (p<0.01), p-mTOR by 62.5% (p<0.01) and LOX-1 by 72.7% (p<0.01). 
  
Conclusion: AGE binds to its cellular receptor RAGE, activates PI3K/PDK1/mTOR signaling 
pathway and thereby induces LOX-1 expression. The induction of LOX-1 by AGE may 
contribute to the increased atherosclerotic risk in diabetes.  
 
